CA2474884A1 - Stimulation of cpt-1 as a means to reduce weight - Google Patents

Stimulation of cpt-1 as a means to reduce weight Download PDF

Info

Publication number
CA2474884A1
CA2474884A1 CA002474884A CA2474884A CA2474884A1 CA 2474884 A1 CA2474884 A1 CA 2474884A1 CA 002474884 A CA002474884 A CA 002474884A CA 2474884 A CA2474884 A CA 2474884A CA 2474884 A1 CA2474884 A1 CA 2474884A1
Authority
CA
Canada
Prior art keywords
cpt
activity
fatty acid
agent
malonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002474884A
Other languages
English (en)
French (fr)
Inventor
Jagan N. Thupari
Leslie E. Landree
Gabriele Ronnett
Francis P. Kuhajda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2474884A1 publication Critical patent/CA2474884A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pediatric Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002474884A 2002-02-08 2003-02-10 Stimulation of cpt-1 as a means to reduce weight Abandoned CA2474884A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35448002P 2002-02-08 2002-02-08
US60/354,480 2002-02-08
PCT/US2003/003839 WO2003066043A1 (en) 2002-02-08 2003-02-10 Stimulation of cpt-1 as a means to reduce weight

Publications (1)

Publication Number Publication Date
CA2474884A1 true CA2474884A1 (en) 2003-08-14

Family

ID=27734382

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002474884A Abandoned CA2474884A1 (en) 2002-02-08 2003-02-10 Stimulation of cpt-1 as a means to reduce weight

Country Status (12)

Country Link
US (4) US20050143467A1 (https=)
EP (1) EP1471906A4 (https=)
JP (2) JP2005523270A (https=)
KR (1) KR20040082417A (https=)
CN (1) CN1313089C (https=)
AU (2) AU2003215111A1 (https=)
BR (1) BR0307421A (https=)
CA (1) CA2474884A1 (https=)
EA (1) EA007029B1 (https=)
IL (1) IL163312A (https=)
MX (1) MXPA04007556A (https=)
WO (1) WO2003066043A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471906A4 (en) * 2002-02-08 2006-02-01 Univ Johns Hopkins Med STIMULATION OF CPT-1 TO REDUCE BODY WEIGHT
EP2386551A1 (en) * 2002-07-09 2011-11-16 Fasgen Inc. Novel compounds, pharmaceutical compositions containing same, and methods of use for same
US20080119548A1 (en) * 2004-03-18 2008-05-22 Ronnett Gabrielle V Control Of Feeding Behavior By Changing Neuronal Energy Balance
CN101022792A (zh) * 2004-05-26 2007-08-22 法斯根有限责任公司 新化合物、包含该化合物的药物组合物及该化合物的应用方法
BRPI0610877A2 (pt) * 2005-06-06 2010-08-03 Hoffmann La Roche compostos, processo para a manufatura dos compostos, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de l-cpt1 e utilização dos mesmos
WO2007014248A2 (en) * 2005-07-26 2007-02-01 Johns Hopkins University Method of reducing food intake
ATE418603T1 (de) * 2005-08-29 2009-01-15 Hoffmann La Roche Kristallstrukturen von carnitine palmitoyltransferase-2 (cpt-2) und deren verwendung
ES2405259B1 (es) * 2011-11-25 2014-09-29 Centro De Investigación Biomédica En Red Fisiopatología De La Obesidad Y Nutrición (Ciberobn) Uso del enantiómero (+)-c75 para el tratamiento de la obesidad.
WO2013155528A2 (en) * 2012-04-13 2013-10-17 Fasgen, Inc. Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US574639A (en) 1897-01-05 Gold-saving device
DE3026368A1 (de) * 1980-07-11 1982-02-18 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Naehrloesung fuer die vollstaendige parenterale ernaehrung und fuer gesteigerte energieproduktion
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
US5914326A (en) * 1997-08-08 1999-06-22 Ambi Inc. Method for promoting weight and fat loss
AU5802499A (en) * 1998-09-01 2000-03-21 Amway Corporation Diet composition and method of weight management
AU784495B2 (en) * 1999-11-12 2006-04-13 Johns Hopkins University School Of Medicine, The Treating cancer by increasing intracellular malonyl coa levels
KR20030016228A (ko) * 2000-02-16 2003-02-26 존스 홉킨스 유니버시티 스쿨 오브 메디슨 신경펩티드 ｙ 농도의 감소에 의해 유도되는 체중 감량
WO2002079501A1 (en) * 2001-03-30 2002-10-10 Trustees Of Boston University Methods and reagents for identifying weight loss promoters and therapeutic uses therefor
EP1471906A4 (en) * 2002-02-08 2006-02-01 Univ Johns Hopkins Med STIMULATION OF CPT-1 TO REDUCE BODY WEIGHT
US20040161803A1 (en) * 2002-04-01 2004-08-19 Corkey Barbara E. Methods and reagents for identifying weight loss promoters and therpeutic uses therefor
EP1534263A4 (en) 2002-07-01 2006-10-11 Fasgen Llc NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF ADMINISTRATION THEREFOR
EP2386551A1 (en) 2002-07-09 2011-11-16 Fasgen Inc. Novel compounds, pharmaceutical compositions containing same, and methods of use for same

Also Published As

Publication number Publication date
AU2003215111A1 (en) 2003-09-02
US20050143467A1 (en) 2005-06-30
CN1638758A (zh) 2005-07-13
KR20040082417A (ko) 2004-09-24
WO2003066043A1 (en) 2003-08-14
BR0307421A (pt) 2004-12-28
IL163312A (en) 2011-12-29
US7459481B2 (en) 2008-12-02
EP1471906A1 (en) 2004-11-03
JP2010047594A (ja) 2010-03-04
US20090124684A1 (en) 2009-05-14
AU2008249144A1 (en) 2008-12-11
MXPA04007556A (es) 2005-12-05
CN1313089C (zh) 2007-05-02
JP2005523270A (ja) 2005-08-04
EP1471906A4 (en) 2006-02-01
US20070087037A1 (en) 2007-04-19
US20050106217A1 (en) 2005-05-19
EA200401052A1 (ru) 2005-02-24
EA007029B1 (ru) 2006-06-30

Similar Documents

Publication Publication Date Title
US20090124684A1 (en) Stimulation Of CPT-1 As A Means To Reduce Weight
Blankson et al. Conjugated linoleic acid reduces body fat mass in overweight and obese humans
Rennie et al. Control of the size of the human muscle mass
Schnuck et al. Characterization of the metabolic effect of β-alanine on markers of oxidative metabolism and mitochondrial biogenesis in skeletal muscle
Le Bacquer et al. 4E‐BP1 and 4E‐BP2 double knockout mice are protected from aging‐associated sarcopenia
Rucker et al. Pantothenic acid
WO2007101191A2 (en) Compositions and methods for reducing cellular fat and for predicting cardiac toxicity and upon treatment with tyrosine kinase inhibitors
Maldonado et al. Actions of p‐synephrine on hepatic enzyme activities linked to carbohydrate metabolism and ATP levels in vivo and in the perfused rat liver
Soda Biological effects of polyamines on the prevention of aging-associated diseases and on lifespan extension
Marotta et al. Fiber type-and fatty acid composition-dependent effects of high-fat diets on rat muscle triacylglyceride and fatty acid transporter protein-1 content
Zhang et al. Inhibition of skeletal muscle atrophy during torpor in ground squirrels occurs through downregulation of MyoG and inactivation of Foxo4
Ghigo et al. Retinoic acid‐induced differentiation in a human neuroblastoma cell line is associated with an increase in nitric oxide synthesis
Kainulainen Effects of chronic exercise and ageing on regional energy metabolism in heart muscle
Roberts et al. Contractile function and energy metabolism of skeletal muscle in rats with secondary carnitine deficiency
PL200460B1 (pl) Dodatek dietetyczny dostarczający energii do mięśni szkieletowych i chroniący szlak sercowo-naczyniowy
Koh et al. Intracellular fatty acid metabolism in skeletal muscle and insulin resistance
Yotsumoto et al. Effects of carnitine palmitoyltransferase I inhibitors on hepatic hypertrophy
Diaz-Rosas et al. The sodium borate relieves the hypertrophic damage induced during pregnancy, it improves contractibility, reduces oxidative stress and stimulates cell proliferation
Braun Physiologic versus pathologic hypertrophy: endurance exercise and chronic pressure overload
Morgan The Cardiac Fatty Acid Metabolic Pathway in Heart Failure
Tobin Mitochondrial biogenesis, signalling pathways involved, and nutrient interactions in response to high intensity interval running
Zbinden et al. Nutrition for Strength Adaptations
Krähenbühl Contractile function and energy metabolism of skeletal muscle in 2 rats with secondary carnitine deficiency 3
Barazzoni Clinical Nutrition University: muscle physiology and bioenergetics
CA3179745A1 (en) Caloric restriction mimetic compositions

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20121106